Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2017

View Archived Issues

Impoyz approved in U.S. for plaque psoriasis

Vertex Pharmaceuticals presents phase III EVOLVE and EXPAND data

ECM binding of checkpoint immunotherapies results in enhanced antitumor activity

Femtogenix synthesizes novel anticancer conjugate compounds

New proteolysis targeting chimera compounds presented by C4 Therapeutics

Prolyl endopeptidase inhibitors identified at Bayer

Daiichi Sankyo and Translational Sciences terminate TS-23 agreement

Enanta Pharmaceuticals presents novel farnesoid X receptor agonists

Istituto Europeo di Oncologia describes novel KDM4C inhibitors

FDA grants fast track designation to Arog Pharmaceuticals' crenolanib

Bayer and Broad Institute extend cancer research partnership

Novel hemorrhagic shock model reveals time window for intervention

Biophytis cleared to begin SARA-INT trial of Sarconeos in Belgium

ALK announces new corporate strategy to transform into broader-based allergy company

FDA approves trastuzumab biosimilar Ogivri

Sanofi ends development of C. difficile vaccine following phase III interim analysis

Sphingotec and Mayo Clinic enter biomarker collaboration

DDP10 identified as novel susceptibility gene for pediatric J wave syndrome

FDA approves Isentress for the treatment of HIV-1 infection in newborns weighing at least 2 kg

FDA approves Repatha to prevent heart attack and stroke, and to lower LDL-C

Taltz approved by FDA for psoriatic arthritis

Takeda enrolling participants in phase II study of TAK-831 in adults with Friedreich ataxia

Aphios developing siRNA-based cure for HIV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...